Article Review: Diagnosis and Treatment of Rhinitis


  • Rahmi Zuraida Universitas Lampung
  • Putu Ristyaning Ayu Sangging Universitas Lampung
  • Rani Himayani Universitas Lampung



Keywords: diagnosis, treatment, rhinitis medicamentosa


Rhinitis medicamentosa (RM) is a condition caused by overuse of nasal decongestants. This can be seen when patients use topical decongestants for more than 5 consecutive days and are accompanied by symptoms of persistent nasal congestion and secretions. The term rhinitis medicamentosa is also called rebound or chemical rhinitis. In addition, rhinitis medicamentosa is also a term for nasal congestion after using drugs other than topical decongestants. These drugs are antihypertensives, antipsychotics, PDE5 inhibitors, analgesics, hormones, and miscellaneous. However, there are differences in the mechanism through which congestion is caused by topical nasal decongestants and oral medications. Very few prospective rhinitis medicamentosa studies have been conducted and most of the knowledge about the condition comes from case reports and histological studies. Histologic changes consistent with rhinitis medicamentosa include nasociliary loss, squamous cell metaplasia, epithelial edema, epithelial cell denudation, goblet cell hyperplasia, increased epidermal growth factor receptor expression, and inflammatory cell infiltration. Because the cumulative dose of nasal decongestants or the length of time needed to start rhinitis medicamentosa has not been definitively determined, these medications should only be used for the shortest period needed. Validated criteria need to be developed and further tests also need to be carried out to establish a better diagnosis. Stopping nasal decongestant use is the first line of treatment for rhinitis medicamentosa. If necessary, intranasal glucocorticosteroids should be used to speed recovery.


Doshi J. Rhinitis Medicamentosa: What an Otolaryngologist Needs to Know. Eur Arch Otorhinolaryngol. 2009;266(5):623–5.

Fowler J, Chin CJ, Massoud E. Rhinitis Medicamentosa: A Nationwide Survey of Canadian Otolaryngologists. J Otolaryngol Head Neck Surg. 2019;48(1):70.

Li LJ, Wang SY, Tsai CY, Wu CJ. Rhinitis Medicamentosa. BMJ Case Rep. 2021;14(11):e247051.

Mortuaire G, De Gabory L, Francois M, Massé G, Bloch F, Brion N, Jankwoski R, Serrano E. Rebound Congestion and Rhinitis Medicamentosa: Nasal Decongestants in Clinical Practice. Critical review of the literature by a Medical Panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137–44.

Scadding GK, Kariyawasam HH. Upper Airway Disease: Rhinitis and Rhinosinusitis. Clinical Respiratory Medicine. 2012:471–86.

Sofyan F. Rhinitis Non Alergi. Medan: Departemen Ilmu Kesehatan Hidung Tenggorok Bedah Kepala dan Leher Fakultas Kedokteran USU; 2011.

Zucker SM, Barton BM, McCoul ED. Management of Rhinitis Medicamentosa: a Systematic Review. Otolaryngol Head Neck Surg. 2019;160(3):429–38.



How to Cite

Rahmi Zuraida, Sangging, P. R. A., & Himayani, R. (2023). Article Review: Diagnosis and Treatment of Rhinitis. Medical Profession Journal of Lampung, 13(4.1), 31-35.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 > >>